CR20220334A - Anticuerpos específicos de apolipoproteína l1 y métodos de uso - Google Patents
Anticuerpos específicos de apolipoproteína l1 y métodos de usoInfo
- Publication number
- CR20220334A CR20220334A CR20220334A CR20220334A CR20220334A CR 20220334 A CR20220334 A CR 20220334A CR 20220334 A CR20220334 A CR 20220334A CR 20220334 A CR20220334 A CR 20220334A CR 20220334 A CR20220334 A CR 20220334A
- Authority
- CR
- Costa Rica
- Prior art keywords
- apol1
- apolipoprotein
- methods
- specific antibodies
- differentiate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente divulgación proporciona anticuerpos anti-apolipoproteína L1 (APOL1), que incluyen anticuerpos anti-APOL1 que diferencian las formas de G0 y G1 de la forma de G2 de APOL1, diferencian APOL1 encontrada en podocitos en lugar de la encontrada en partículas de HDL en suero y diferencian APOL1 de apolipoproteínas L2, L3, L4 y L6 (APOL2, APOL3, APOL4 y APOL6), y los métodos para su uso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962953097P | 2019-12-23 | 2019-12-23 | |
PCT/US2020/066377 WO2021133723A2 (en) | 2019-12-23 | 2020-12-21 | Apolipoprotein l1-specific antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220334A true CR20220334A (es) | 2022-08-26 |
Family
ID=74191928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220334A CR20220334A (es) | 2019-12-23 | 2020-12-21 | Anticuerpos específicos de apolipoproteína l1 y métodos de uso |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230071609A1 (es) |
EP (1) | EP4081294A2 (es) |
JP (1) | JP2023509390A (es) |
KR (1) | KR20220118527A (es) |
CN (1) | CN115515678A (es) |
AU (1) | AU2020412609A1 (es) |
BR (1) | BR112022012439A2 (es) |
CA (1) | CA3165504A1 (es) |
CL (1) | CL2022001714A1 (es) |
CO (1) | CO2022010235A2 (es) |
CR (1) | CR20220334A (es) |
IL (1) | IL294131A (es) |
MX (1) | MX2022007746A (es) |
PE (1) | PE20221186A1 (es) |
WO (1) | WO2021133723A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023086901A1 (en) * | 2021-11-12 | 2023-05-19 | Virginia Tech Intellectual Properties, Inc. | Borrelia burgdorferi peptidoglycan detection methods |
US11976067B2 (en) | 2022-01-18 | 2024-05-07 | Maze Therapeutics, Inc. | APOL1 inhibitors and methods of use |
WO2023178208A2 (en) * | 2022-03-16 | 2023-09-21 | Stcube & Co., Inc. | Btn1a1 binding proteins and methods of use thereof |
WO2024050524A1 (en) * | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
JP2003505082A (ja) | 1999-07-26 | 2003-02-12 | ジェネンテック・インコーポレーテッド | 新規なポリヌクレオチドとその使用法 |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
US20080044455A1 (en) | 2006-08-21 | 2008-02-21 | Chaim Welczer | Tonsillitus Treatment |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
CN101687915B8 (zh) | 2007-04-03 | 2018-08-03 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
NZ598962A (en) | 2009-09-16 | 2014-12-24 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
EP2748202B1 (en) | 2011-08-23 | 2018-07-04 | Roche Glycart AG | Bispecific antigen binding molecules |
JP6339015B2 (ja) | 2011-08-23 | 2018-06-06 | ロシュ グリクアート アーゲー | 二重特異性t細胞活性化抗原結合分子 |
RU2605390C2 (ru) | 2011-08-23 | 2016-12-20 | Рош Гликарт Аг | Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения |
WO2015095539A1 (en) | 2013-12-20 | 2015-06-25 | Genentech, Inc. | Dual specific antibodies |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP3174897B1 (en) | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
MA40510A (fr) | 2014-08-04 | 2017-06-14 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t |
WO2016077369A1 (en) * | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Animal model for nephropathy and agents for treating the same |
KR102668727B1 (ko) | 2015-04-24 | 2024-05-28 | 제넨테크, 인크. | 다중특이적 항원-결합 단백질 |
-
2020
- 2020-12-21 PE PE2022001163A patent/PE20221186A1/es unknown
- 2020-12-21 EP EP20842842.5A patent/EP4081294A2/en active Pending
- 2020-12-21 AU AU2020412609A patent/AU2020412609A1/en active Pending
- 2020-12-21 CA CA3165504A patent/CA3165504A1/en active Pending
- 2020-12-21 KR KR1020227025218A patent/KR20220118527A/ko unknown
- 2020-12-21 MX MX2022007746A patent/MX2022007746A/es unknown
- 2020-12-21 WO PCT/US2020/066377 patent/WO2021133723A2/en active Application Filing
- 2020-12-21 CR CR20220334A patent/CR20220334A/es unknown
- 2020-12-21 BR BR112022012439A patent/BR112022012439A2/pt unknown
- 2020-12-21 CN CN202080096952.1A patent/CN115515678A/zh active Pending
- 2020-12-21 JP JP2022538362A patent/JP2023509390A/ja active Pending
- 2020-12-21 IL IL294131A patent/IL294131A/en unknown
-
2022
- 2022-06-22 CL CL2022001714A patent/CL2022001714A1/es unknown
- 2022-06-22 US US17/846,744 patent/US20230071609A1/en active Pending
- 2022-07-19 CO CONC2022/0010235A patent/CO2022010235A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20221186A1 (es) | 2022-08-05 |
CL2022001714A1 (es) | 2023-03-03 |
KR20220118527A (ko) | 2022-08-25 |
WO2021133723A2 (en) | 2021-07-01 |
CO2022010235A2 (es) | 2022-08-09 |
IL294131A (en) | 2022-08-01 |
CA3165504A1 (en) | 2021-07-01 |
AU2020412609A1 (en) | 2022-06-16 |
CN115515678A (zh) | 2022-12-23 |
MX2022007746A (es) | 2022-10-07 |
WO2021133723A3 (en) | 2021-08-05 |
JP2023509390A (ja) | 2023-03-08 |
EP4081294A2 (en) | 2022-11-02 |
BR112022012439A2 (pt) | 2022-09-06 |
US20230071609A1 (en) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220334A (es) | Anticuerpos específicos de apolipoproteína l1 y métodos de uso | |
UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
CL2022002771A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y su uso (divisional de cl 201703195). | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
PE20200733A1 (es) | Inhibidores de kras g 12c y metodos para su uso | |
CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
GT199900147A (es) | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
CL2007000361A1 (es) | Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc. | |
ES2377720T3 (es) | Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos. | |
CR20180605A (es) | Anticuerpos anti-cd40 y sus usos | |
CR20190105A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
CR20150088A (es) | Anticuerpos anti-notch1 nrr | |
PA8598901A1 (es) | Compuesto de quinolina y quinoxalina | |
BR112017009440A2 (pt) | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) | |
CO2017011238A2 (es) | Anticuerpos anti-c1s humanizados | |
CL2020002103A1 (es) | Anticuerpos anti-htra1 y metodos de uso de los mismos. (divisional solicitud 201801139) | |
CL2018003349A1 (es) | Combinación de anticuerpo anti-cd20, inhibidor selectivo de pelasa de p13, e inhibidor de btk para tratar trastornos proliferativos de células b. | |
CL2021000328A1 (es) | Inhibidores de transglutaminasa 2 (tg2) | |
MX2021010545A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar. | |
UY28097A1 (es) | Activadores de ppar | |
CL2023002223A1 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
CO2020007895A2 (es) | Inhibidores de histona acetiltransferasa de la familia myst | |
WO2016170124A3 (en) | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior | |
CL2016000939A1 (es) | Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende. | |
CL2022000492A1 (es) | Proceso para la preparación de estetrol de alta pureza. |